Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif

Date: 11 May 2017



Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported internationally in patients treated with Keytruda® (pembrolizumab) in clinical trials and the post-marketing setting. There were a total of eight (8) serious cases of SJS and two (2) serious cases of TEN, including one fatal case each of SJS and TEN.

Healthcare professionals are advised to counsel patients on the risks and benefits of pembrolizumab, including the risk and early symptoms of SJS and TEN. Pembrolizumab should be withheld if symptoms of SJS or TEN occur, and the patient should be referred for specialised care. If SJS or TEN is confirmed, pembrolizumab should be permanently discontinued.

A Direct Healthcare Professional Communication (DHPC) has been issued by Merck Sharp & Dohme (M) Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to this DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400



Image   Image   Image   Image  


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Khamis 20 Jun 2024, 10:17:13.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Menu Utama